QuantideX® NGS RNA Lung Cancer Kit

rna-lung-cancer-kit-box-photo-for-webThe QuantideX® NGS RNA Lung Cancer Kit* is a clinical research tool enabling the simultaneous assessment of fusions, exon skipping, and other expression targets frequently observed in non-small cell lung cancer (NSCLC). Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, this kit offers a simple, sensitive, and reliable NGS assay for routine investigation of NSCLC samples.

Features & Benefits

The QuantideX NGS RNA Lung Cancer Kit offers a unique NGS-in-a-Box™ solution that provides unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE NSCLC samples.

Reduced Complexity
Assay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration

  • Single assay for a broad range of important NSCLC fusion targets
  • All-inclusive reagents from reverse transcription to NGS-ready library
  • Fully integrated data analysis pipeline

Optimized Workflow
Efficient workflow leads to lower operational costs and reduced hands-on and total turnaround time*

  • Reduced labor vs. current commercially available kits
  • Improved turnaround time enables higher throughput

*Internal data on file.

Quality Performance
Highly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures

  • Highly sensitive detection of RNA-based fusions
  • Low input (~20ng) of RNA from FFPE
  • Sample-Aware™ bioinformatics analysis and sample quality control

*For Research Use Only. Not for use in Diagnostic procedures.

Product Description

Relevant Content
A focus on only the most important lung cancer fusion genes, MET exon 14 skipping events, 3’/5′ imbalances and mRNA expression from multiple published data sources such as COSMIC, ClinicalTrials.gov, NCCN Guidelines, etc.

  • 107 NSCLC-relevant fusions
  • ALK, RET, ROS1, NTRK1 & PDGFRA 3’/5’ imbalances
  • MET exon 14 skipping events (e13/e14; e14/e15; e13/e15)
  • 23 mRNA targets, plus 3 endogenous control transcripts

workflow-without-mrna-for-web

A Fully Integrated Workflow
A unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to run right out of the box.

Includes:

  • RT-PCR reagents
  • A unique RNA Lung Cancer Sample QC kit (QuantideX qPCR RNA Assay (Lung))
  • Gene-specific PCR primers and Master Mix reagents
  • Barcodes for sample multiplexing
  • Library purification and quantification reagents
  • Integrated data analysis and reporting software (QuantideX NGS Reporter)

workflow-image-for-web


Rapid & Efficient
Adopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.

  • Fully integrated workflow reduces complexity and ensures reliable reagent quality
  • Push-button analysis & reporting makes bioinformatics easy and efficient, regardless of experience level
  • Integrated kit reduces workflow time by over 50% than competing NGS panels

workflowanalyis_comparew-archer_updated

Performance Data
QuantideX NGS Assay is capable of detecting fusions and splice variants down to 1:100 cells. (a) Admixture of MET exon 14 positive cell line in the background of wild-type cells, and (b) fusion, and (c) 3’/5’ imbalance status for an admixture of EML4-ALK positive FFPE in the background of a negative FFPE.

Figure 3a

Figure 3a

Figure 3b

Figure 3b

Figure 3c

Figure 3c

 

QuantideX® NGS Reporter

Quantidex-Reporter-ComputerPush-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.

Runs directly on lab desktop – Install locally on a Windows® desktop computer. No prior bioinformatics experience or large server environments required.

Comprehensive reporting – Full bioinformatics and reporting of variants (SNVs, SNPs, Indels, fusions), and standard QC metrics are automatically calculated.

Integrates QuantideX RNA/DNA QC AssaySample-Aware™ bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.

Seamless updates offered with new panel designs & variant annotation – Software updates allow new panels to be adopted without re-investing in analytics when the Asuragen QuantideX NGS product line is adopted.

Contact us to request the QuantideX Reporter

Ordering

Product Name Number of Reactions Catalog Number
QuantideX NGS RNA Lung Cancer Kit* 48 49602
QuantideX NGS RNA Lung Cancer Kit* 192 49603

T 1-877-777-1874; 512-681-5200
F 512-681-5202
E orders@asuragen.com

*For Research Use Only. Not for use in Diagnostic procedures.

QuantideX® NGS RNA Lung Cancer Kit

rna-lung-cancer-kit-box-photo-for-webThe QuantideX® NGS RNA Lung Cancer Kit* is a clinical research tool enabling the simultaneous assessment of fusions, exon skipping, and other expression targets frequently observed in non-small cell lung cancer (NSCLC). Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, this kit offers a simple, sensitive, and reliable NGS assay for routine investigation of NSCLC samples.

Features & Benefits

The QuantideX NGS RNA Lung Cancer Kit offers a unique NGS-in-a-Box™ solution that provides unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE NSCLC samples.

Reduced Complexity
Assay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration

  • Single assay for a broad range of important NSCLC fusion targets
  • All-inclusive reagents from reverse transcription to NGS-ready library
  • Fully integrated data analysis pipeline

Optimized Workflow
Efficient workflow leads to lower operational costs and reduced hands-on and total turnaround time*

  • Reduced labor vs. current commercially available kits
  • Improved turnaround time enables higher throughput

*Internal data on file.

Quality Performance
Highly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures

  • Highly sensitive detection of RNA-based fusions
  • Low input (~20ng) of RNA from FFPE
  • Sample-Aware™ bioinformatics analysis and sample quality control

*For Research Use Only. Not for use in Diagnostic procedures.

Product Description

Relevant Content
A focus on only the most important lung cancer fusion genes, MET exon 14 skipping events, 3’/5′ imbalances and mRNA expression from multiple published data sources such as COSMIC, ClinicalTrials.gov, NCCN Guidelines, etc.

  • 107 NSCLC-relevant fusions
  • ALK, RET, ROS1, NTRK1 & PDGFRA 3’/5’ imbalances
  • MET exon 14 skipping events (e13/e14; e14/e15; e13/e15)
  • 23 mRNA targets, plus 3 endogenous control transcripts

workflow-without-mrna-for-web

A Fully Integrated Workflow
A unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to run right out of the box.

Includes:

  • RT-PCR reagents
  • A unique RNA Lung Cancer Sample QC kit (QuantideX qPCR RNA Assay (Lung))
  • Gene-specific PCR primers and Master Mix reagents
  • Barcodes for sample multiplexing
  • Library purification and quantification reagents
  • Integrated data analysis and reporting software (QuantideX NGS Reporter)

workflow-image-for-web


Rapid & Efficient
Adopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.

  • Fully integrated workflow reduces complexity and ensures reliable reagent quality
  • Push-button analysis & reporting makes bioinformatics easy and efficient, regardless of experience level
  • Integrated kit reduces workflow time by over 50% than competing NGS panels

workflowanalyis_comparew-archer_updated

Performance Data
QuantideX NGS Assay is capable of detecting fusions and splice variants down to 1:100 cells. (a) Admixture of MET exon 14 positive cell line in the background of wild-type cells, and (b) fusion, and (c) 3’/5’ imbalance status for an admixture of EML4-ALK positive FFPE in the background of a negative FFPE.

Figure 3a

Figure 3a

Figure 3b

Figure 3b

Figure 3c

Figure 3c

 

QuantideX® NGS Reporter

Quantidex-Reporter-ComputerPush-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.

Runs directly on lab desktop – Install locally on a Windows® desktop computer. No prior bioinformatics experience or large server environments required.

Comprehensive reporting – Full bioinformatics and reporting of variants (SNVs, SNPs, Indels, fusions), and standard QC metrics are automatically calculated.

Integrates QuantideX RNA/DNA QC AssaySample-Aware™ bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.

Seamless updates offered with new panel designs & variant annotation – Software updates allow new panels to be adopted without re-investing in analytics when the Asuragen QuantideX NGS product line is adopted.

Contact us to request the QuantideX Reporter

Ordering

Product Name Number of Reactions Catalog Number
QuantideX NGS RNA Lung Cancer Kit* 48 49602
QuantideX NGS RNA Lung Cancer Kit* 192 49603

T 1-877-777-1874; 1-512-681-5200
F 1-512-681-5202
E orders@asuragen.com

*For Research Use Only. Not for use in Diagnostic procedures.

Back To
Top

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close